| Literature DB >> 36100791 |
Vicki J Swier1, Katherine A White1, Tyler B Johnson1, Jessica C Sieren2,3, Hans J Johnson4, Kevin Knoernschild2,3, Xiaojun Wang5, Frank A Rohret5, Christopher S Rogers5, David A Pearce1,6, Jon J Brudvig1,6, Jill M Weimer7,8.
Abstract
CLN2 Batten disease is a lysosomal disorder in which pathogenic variants in CLN2 lead to reduced activity in the enzyme tripeptidyl peptidase 1. The disease typically manifests around 2 to 4 years of age with developmental delay, ataxia, seizures, inability to speak and walk, and fatality between 6 and 12 years of age. Multiple Cln2 mouse models exist to better understand the etiology of the disease; however, these models are unable to adequately recapitulate the disease due to differences in anatomy and physiology, limiting their utility for therapeutic testing. Here, we describe a new CLN2R208X/R208X porcine model of CLN2 disease. We present comprehensive characterization showing behavioral, pathological, and visual phenotypes that recapitulate those seen in CLN2 patients. CLN2R208X/R208X miniswine present with gait abnormalities at 6 months of age, ERG waveform declines at 6-9 months, vision loss at 11 months, cognitive declines at 12 months, seizures by 15 months, and early death at 18 months due to failure to thrive. CLN2R208X/R208X miniswine also showed classic storage material accumulation and glial activation in the brain at 6 months, and cortical atrophy at 12 months. Thus, the CLN2R208X/R208X miniswine model is a valuable resource for biomarker discovery and therapeutic development in CLN2 disease.Entities:
Keywords: CLN2 Batten disease; Cortical atrophy; Electroretinogram a- and b-waves; Gait; Miniswine; Seizures
Year: 2022 PMID: 36100791 DOI: 10.1007/s13311-022-01296-7
Source DB: PubMed Journal: Neurotherapeutics ISSN: 1878-7479 Impact factor: 6.088